Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1967 2
1968 1
1971 1
1973 1
1974 2
1976 1
1977 4
1978 1
1979 2
1983 1
1984 4
1985 2
1987 3
1988 2
1989 3
1990 2
1991 1
1992 3
1993 5
1994 3
1995 2
1996 2
1997 3
1998 4
1999 2
2000 1
2001 1
2002 5
2003 8
2004 1
2006 3
2007 3
2008 8
2009 4
2010 5
2011 5
2012 8
2013 7
2014 8
2015 6
2016 11
2017 9
2018 9
2019 4
2020 8
2021 6
2022 2
2023 3
2024 7
2025 17
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Among authors: papas a. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: papas a. Arthritis Rheumatol. 2025 May;77(5):560-570. doi: 10.1002/art.43059. Epub 2025 Jan 5. Arthritis Rheumatol. 2025. PMID: 39557617 Clinical Trial.
Réduction des risques en addictologie.
Papas A. Papas A. Rev Infirm. 2018 Jan;67(237):15. doi: 10.1016/j.revinf.2017.11.001. Rev Infirm. 2018. PMID: 29331184 French. No abstract available.
Le refus de soins.
Papas A. Papas A. Rev Infirm. 2016 Oct;224:15. doi: 10.1016/j.revinf.2016.08.015. Rev Infirm. 2016. PMID: 27719785 French. No abstract available.
Osons ouvrir le dialogue sur la fin de vie.
Papas A. Papas A. Rev Infirm. 2018 Aug-Sep;67(243):1. doi: 10.1016/j.revinf.2018.07.001. Rev Infirm. 2018. PMID: 30262000 French. No abstract available.
Prévenir la perte de sens au travail.
Papas A. Papas A. Rev Infirm. 2016 Nov;65(225):1. doi: 10.1016/j.revinf.2016.09.004. Rev Infirm. 2016. PMID: 27968961 French. No abstract available.
L'amputation en contexte post-traumatique.
Papas A, Warnet S. Papas A, et al. Rev Infirm. 2015 Mar;209:15. doi: 10.1016/j.revinf.2014.12.005. Rev Infirm. 2015. PMID: 26145127 French. No abstract available.
196 results